xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06030245</url>
    </required_header>
    <id_info>
      <org_study_id>DECLIC</org_study_id>
      <nct_id>NCT06030245</nct_id>
    </id_info>
    <brief_title>Clostridioides Difficile Infection: Analyzing CLInic Evolution and Bacterial Clearance</brief_title>
    <acronym>DECLIC</acronym>
    <official_title>Clostridioides Difficile Infection: Prospective Cohort Analyzing CLInic Evolution and Bacterial Clearance</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Fondation Hôpital Saint-Joseph</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Fondation Hôpital Saint-Joseph</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        Clostridioides difficile (formerly Clostridium) is a bacterium found in the form of spores&#xD;
        (resistance form) in the environment to which patients may be exposed. This bacterium used to&#xD;
        belong to the Clostridium genus, but analysis of its 16S ribosomal RNA in 2016 led to its&#xD;
        being distinguished from it. Once the spore has been ingested, it can germinate in vegetative&#xD;
        form (the active form of the bacterium), taking on the appearance of a Gram-positive bacillus&#xD;
        that will colonize the digestive microbiota. This preliminary stage of digestive colonization&#xD;
        by the bacteria is facilitated by certain factors, notably nasogastric probing, antacids,&#xD;
        etc. Antibiotics, for their part, disrupt the bacteria of the digestive microbiota&#xD;
        (dysbiosis), thus facilitating the implantation of C. difficile. Certain strains (known as&#xD;
        toxigenic) will produce the main virulence factors: toxins A (TcdA) and B (TcdB) ± a third&#xD;
        toxin (binary toxin or CDT), and thus cause the main clinical signs of digestive infection,&#xD;
        particularly in patients with risk factors for C. difficile infection (progressive cancer,&#xD;
        immunodepression, etc.).&#xD;
  &#xD;
        Clostridioides difficile infection (CDI) is characterized by variable clinical presentations,&#xD;
        ranging from simple watery diarrhea without colitis, which often resolves spontaneously, to&#xD;
        severe forms with complications such as pseudomembranous colitis, intestinal perforation or&#xD;
        septic shock, which have a very poor prognosis.&#xD;
  &#xD;
        Management of this type of CDI relies mainly on the oral administration of anti-clostridium&#xD;
        difficile antibiotics such as fidaxomicin (FDX) or vancomycin (VAN) for 10 days, as&#xD;
        recommended by the European ESCMID, British and American IDSA guidelines. Oral metronidazole&#xD;
        is recommended only in the absence of availability of the first two molecules (community&#xD;
        use). Despite this treatment, one of the main characteristics of CDI is a high recurrence&#xD;
        rate, which can reach 25% of cases. With FDX, recurrence rates appear to be lower, especially&#xD;
        as its administration regimen is optimized. Nevertheless, its high cost is a barrier to its&#xD;
        wider use.&#xD;
  &#xD;
        In view of the high cost to the community of treating recurrences, and the reduced quality of&#xD;
        life of patients suffering from these recurrences, which are sometimes multiple and highly&#xD;
        incapacitating, reducing the occurrence of recurrences is a major challenge. A better&#xD;
        understanding of the factors leading to recurrence is therefore a prerequisite for optimizing&#xD;
        CDI prevention and treatment strategies.&#xD;
  &#xD;
        The study of colonic mucosal immunity (aimed at quantifying IgA in stools) could also&#xD;
        contribute to a better understanding of patient progress.&#xD;
  &#xD;
        All these issues surrounding CDI and its management justify the setting up of a prospective&#xD;
        cohort for the longitudinal follow-up of infected patients, enabling us to study the&#xD;
        digestive clearance of the bacteria according to various factors, notably the digestive&#xD;
        microbiota and the mucosal immune response.&#xD;
      </textblock>
    </brief_summary>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">September 13, 2023</start_date>
    <completion_date type="Anticipated">November 13, 2025</completion_date>
    <primary_completion_date type="Anticipated">September 12, 2025</primary_completion_date>
    <study_type>Observational</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <observational_model>Cohort</observational_model>
      <time_perspective>Prospective</time_perspective>
    </study_design_info>
    <primary_outcome>
      <measure>Duration of delay between diagnosis of CDI and early or late elimination of C. difficile</measure>
      <time_frame>Month 2</time_frame>
      <description>This outcome corresponds to the kinetics of C. difficile elimination, and the time taken for the various microbiological tests (EIA, immunochromatography (ICT), culturomic and specific qPCR tests) detecting C. difficile in stools to become negative, from the day of diagnosis (i.e. before treatment was started), during the 10-day treatment period and after the end of treatment.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Confronting digestive microbiota dysbiosis with C. difficile elimination kinetics</measure>
      <time_frame>Month 2</time_frame>
      <description>This outcome corresponds to the comparison in terms of number and type of digestive microbiota as a function of C. difficile elimination kinetics before treatment (at the time of diagnosis), at the end of 10 days of CDI treatment and after the end of treatment.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Impact of antibiotics prescribed for the treatment of CDI after 10 days of treatment</measure>
      <time_frame>Day 10</time_frame>
      <description>This outcome corresponds to the comparison in terms of number and type of diversity of digestive microbiota according to the type of anti-C. difficile antibiotic prescribed at the end of treatment, compared with the number and type of digestive observed at the time of diagnosis, i.e. before the start of treatment.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Determination of the form in which C. difficile persists in the digestive microbiota during treatment and after the end of treatment until it is eliminated.</measure>
      <time_frame>Month 2</time_frame>
      <description>This outcome corresponds to the type of the bacterial form (vegetative or spore-forming) that persists during and after ICD treatment by qPCR, Propidium monoazide - qPCR (PMA-qPCR) (viable or dead bacteria) and culturomics until digestive clearance of the bacteria.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Evaluation of the colonic and salivary mucosal immune response of included patients, in relation to patient progress and C. difficile elimination kinetics.</measure>
      <time_frame>Month 2</time_frame>
      <description>This outcome corresponds to the number of participants with a development of a C. difficile anti-toxin IgA response and correlation of colonic/salivary IgA levels after ICD with patient course (single, recurrent and severe forms) and C. difficile elimination kinetics.</description>
    </secondary_outcome>
    <number_of_groups>1</number_of_groups>
    <enrollment type="Anticipated">100</enrollment>
    <condition>Clostridium Difficile Infections</condition>
    <arm_group>
      <arm_group_label>Patients with Clostridioides infection</arm_group_label>
      <description>The following procedures are specific to this test: 8 additional stool swabs (or Fecal Swab in the absence of stool output) to that of the initial diagnosis, plus four saliva swabs. Rectal swabs may cause anal irritation. The patient must also complete a stool collection form.</description>
    </arm_group>
    <biospec_retention>Samples Without DNA</biospec_retention>
    <biospec_descr>
      <textblock>
        additional stool samples (or Fecal Swab in the absence of stool output) to that of the&#xD;
        initial diagnosis, as well as saliva samples&#xD;
      </textblock>
    </biospec_descr>
    <eligibility>
      <study_pop>
        <textblock>
          Patients hospitalized in a department of Hôpital Paris Saint-Joseph with microbiologically&#xD;
          documented Clostridioides difficile infection or microbiologically documented recurrence of&#xD;
          Clostridioides difficile infection, for whom treatment of Clostridioides difficile&#xD;
          infection is to be initiated.&#xD;
        </textblock>
      </study_pop>
      <sampling_method>Non-Probability Sample</sampling_method>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Patients over 18 years of age&#xD;
  &#xD;
            -  Patients hospitalized in a department of GH Paris Saint-Joseph with a&#xD;
               microbiologically documented Clostridioides difficile infection or a microbiologically&#xD;
               documented Clostridioides difficile recurrence.&#xD;
  &#xD;
            -  Patient to be treated for Clostridioides difficile infection&#xD;
  &#xD;
            -  French-speaking patient&#xD;
  &#xD;
            -  Patients who do not object to their participation in the study&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Patients under guardianship or curatorship&#xD;
  &#xD;
            -  Patient deprived of liberty&#xD;
  &#xD;
            -  Patient under court protection&#xD;
  &#xD;
            -  Pregnant or breast-feeding patient&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Assaf MIZRAHI, MD</last_name>
      <role>Principal Investigator</role>
      <affiliation>Fondation Hôpital Saint-Joseph</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Assaf MIZRAHI, MD</last_name>
      <phone>144127030</phone>
      <phone_ext>+33</phone_ext>
      <email>amizrahi@ghpsj.fr</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Helene BEAUSSIER, PharmD, PhD</last_name>
      <phone>144127883</phone>
      <phone_ext>+33</phone_ext>
      <email>crc@ghpsj.fr</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>Fondation Hôpital Saint-Joseph</name>
        <address>
          <city>Paris</city>
          <zip>75014</zip>
          <country>France</country>
        </address>
      </facility>
      <contact>
        <last_name>Assaf MIZRAHI, MD</last_name>
      </contact>
    </location>
    <location_countries>
      <country>France</country>
    </location_countries>
    <link>
      <url>https://www.gov.uk/government/consultations/clostridioides-difficile-infection-guidance-on-management-and-treatment</url>
      <description>Clostridioides difficile infection: guidance on management and treatment [Internet]. GOV.UK. 2022</description>
    </link>
    <reference>
      <citation>Lawson PA, Citron DM, Tyrrell KL, Finegold SM. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Prevot 1938. Anaerobe. 2016 Aug;40:95-9. doi: 10.1016/j.anaerobe.2016.06.008. Epub 2016 Jun 28.</citation>
      <PMID>27370902</PMID>
    </reference>
    <reference>
      <citation>Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021 Sep 7;73(5):e1029-e1044. doi: 10.1093/cid/ciab549.</citation>
      <PMID>34164674</PMID>
    </reference>
    <reference>
      <citation>van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, Krutova M, Noren T, Allerberger F, Coia JE, Goorhuis A, van Rossen TM, Ooijevaar RE, Burns K, Scharvik Olesen BR, Tschudin-Sutter S, Wilcox MH, Vehreschild MJGT, Fitzpatrick F, Kuijper EJ; Guideline Committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect. 2021 Dec;27 Suppl 2:S1-S21. doi: 10.1016/j.cmi.2021.09.038. Epub 2021 Oct 20.</citation>
      <PMID>34678515</PMID>
    </reference>
    <reference>
      <citation>Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S; OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012 Apr;12(4):281-9. doi: 10.1016/S1473-3099(11)70374-7. Epub 2012 Feb 8.</citation>
      <PMID>22321770</PMID>
    </reference>
    <reference>
      <citation>Guery B, Menichetti F, Anttila VJ, Adomakoh N, Aguado JM, Bisnauthsing K, Georgopali A, Goldenberg SD, Karas A, Kazeem G, Longshaw C, Palacios-Fabrega JA, Cornely OA, Vehreschild MJGT; EXTEND Clinical Study Group. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. Lancet Infect Dis. 2018 Mar;18(3):296-307. doi: 10.1016/S1473-3099(17)30751-X. Epub 2017 Dec 19.</citation>
      <PMID>29273269</PMID>
    </reference>
    <reference>
      <citation>Guery B, Berger P, Gauzit R, Gourdon M, Barbut F; DAFNE study group; Dafne Study Group, Bemer P, Bessede E, Camou F, Cattoir V, Couzigou C, Descamps D, Dinh A, Laurans C, Lavigne JP, Lechiche C, Leflon-Guibout V, Le Monnier A, Levast M, Mootien JY, N'Guyen Y, Piroth L, Prazuck T, Rogeaux O, Roux AL, Vachee A, Vernet Garnier V, Wallet F. A prospective, observational study of fidaxomicin use for Clostridioides difficile infection in France. J Int Med Res. 2021 Jun;49(6):3000605211021278. doi: 10.1177/03000605211021278.</citation>
      <PMID>34162264</PMID>
    </reference>
    <reference>
      <citation>Watt M, Dinh A, Le Monnier A, Tilleul P. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France. J Med Econ. 2017 Jul;20(7):678-686. doi: 10.1080/13696998.2017.1302946. Epub 2017 Mar 16.</citation>
      <PMID>28299963</PMID>
    </reference>
    <reference>
      <citation>Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001 Jan 20;357(9251):189-93. doi: 10.1016/S0140-6736(00)03592-3.</citation>
      <PMID>11213096</PMID>
    </reference>
    <reference>
      <citation>Chilton CH, Crowther GS, Todhunter SL, Ashwin H, Longshaw CM, Karas A, Wilcox MH. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model. J Antimicrob Chemother. 2015 Sep;70(9):2598-607. doi: 10.1093/jac/dkv156. Epub 2015 Jun 14.</citation>
      <PMID>26078392</PMID>
    </reference>
    <reference>
      <citation>Le Monnier A, Candela T, Mizrahi A, Bille E, Bourgeois-Nicolaos N, Cattoir V, Farfour E, Grall I, Lecointe D, Limelette A, Marcade G, Poilane I, Poupy P, Kansau I, Zahar JR, Pilmis B; GMC Group. One-day prevalence of asymptomatic carriage of toxigenic and non-toxigenic Clostridioides difficile in 10 French hospitals. J Hosp Infect. 2022 Nov;129:65-74. doi: 10.1016/j.jhin.2022.05.011. Epub 2022 May 28.</citation>
      <PMID>35640734</PMID>
    </reference>
    <reference>
      <citation>Le Monnier A, Duburcq A, Zahar JR, Corvec S, Guillard T, Cattoir V, Woerther PL, Fihman V, Lalande V, Jacquier H, Mizrahi A, Farfour E, Morand P, Marcade G, Coulomb S, Torreton E, Fagnani F, Barbut F; GMC Study Group. Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals. J Hosp Infect. 2015 Oct;91(2):117-22. doi: 10.1016/j.jhin.2015.06.017. Epub 2015 Jul 22.</citation>
      <PMID>26253518</PMID>
    </reference>
    <reference>
      <citation>Meza-Torres J, Auria E, Dupuy B, Tremblay YDN. Wolf in Sheep's Clothing: Clostridioides difficile Biofilm as a Reservoir for Recurrent Infections. Microorganisms. 2021 Sep 10;9(9):1922. doi: 10.3390/microorganisms9091922.</citation>
      <PMID>34576818</PMID>
    </reference>
    <reference>
      <citation>Barbut F, Galperine T, Vanhems P, Le Monnier A, Durand-Gasselin B, Canis F, Jeanbat V, Duburcq A, Alami S, Bensoussan C, Fagnani F. Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting. Health Qual Life Outcomes. 2019 Jan 11;17(1):6. doi: 10.1186/s12955-019-1081-5.</citation>
      <PMID>30634997</PMID>
    </reference>
    <reference>
      <citation>Debast SB, Bauer MP, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014 Mar;20 Suppl 2:1-26. doi: 10.1111/1469-0691.12418.</citation>
      <PMID>24118601</PMID>
    </reference>
    <reference>
      <citation>Sethi AK, Al-Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect Control Hosp Epidemiol. 2010 Jan;31(1):21-7. doi: 10.1086/649016.</citation>
      <PMID>19929371</PMID>
    </reference>
    <reference>
      <citation>Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis. 1996 May;22(5):813-8. doi: 10.1093/clinids/22.5.813. Erratum In: Clin Infect Dis 1996 Aug;23(2):423.</citation>
      <PMID>8722937</PMID>
    </reference>
    <reference>
      <citation>Saha S, Yadav D, Pardi R, Patel R, Khanna S, Pardi D. Kinetics of polymerase chain reaction positivity in patients with Clostridioides difficile infection. Therap Adv Gastroenterol. 2021 Oct 8;14:17562848211050443. doi: 10.1177/17562848211050443. eCollection 2021.</citation>
      <PMID>34646361</PMID>
    </reference>
    <reference>
      <citation>Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000 Feb 10;342(6):390-7. doi: 10.1056/NEJM200002103420604.</citation>
      <PMID>10666429</PMID>
    </reference>
    <reference>
      <citation>Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB; MODIFY I and MODIFY II Investigators. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med. 2017 Jan 26;376(4):305-317. doi: 10.1056/NEJMoa1602615.</citation>
      <PMID>28121498</PMID>
    </reference>
    <reference>
      <citation>Ahluwalia B, Magnusson MK, Ohman L. Mucosal immune system of the gastrointestinal tract: maintaining balance between the good and the bad. Scand J Gastroenterol. 2017 Nov;52(11):1185-1193. doi: 10.1080/00365521.2017.1349173. Epub 2017 Jul 12.</citation>
      <PMID>28697651</PMID>
    </reference>
    <reference>
      <citation>Nibbering B, Gerding DN, Kuijper EJ, Zwittink RD, Smits WK. Host Immune Responses to Clostridioides difficile: Toxins and Beyond. Front Microbiol. 2021 Dec 21;12:804949. doi: 10.3389/fmicb.2021.804949. eCollection 2021.</citation>
      <PMID>34992590</PMID>
    </reference>
    <reference>
      <citation>Bridgman SL, Konya T, Azad MB, Guttman DS, Sears MR, Becker AB, Turvey SE, Mandhane PJ, Subbarao P; CHILD Study Investigators; Scott JA, Field CJ, Kozyrskyj AL. High fecal IgA is associated with reduced Clostridium difficile colonization in infants. Microbes Infect. 2016 Sep;18(9):543-9. doi: 10.1016/j.micinf.2016.05.001. Epub 2016 May 24.</citation>
      <PMID>27235197</PMID>
    </reference>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 31, 2023</study_first_submitted>
    <study_first_submitted_qc>August 31, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">September 8, 2023</study_first_posted>
    <last_update_submitted>September 11, 2023</last_update_submitted>
    <last_update_submitted_qc>September 11, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 13, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Infections</mesh_term>
      <mesh_term>Communicable Diseases</mesh_term>
      <mesh_term>Clostridium Infections</mesh_term>
    </condition_browse>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06030245
  org study id: DECLIC
  nct id: NCT06030245
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  Clostridioides difficile (formerly Clostridium) is a bacterium found in the form of spores
        (resistance form) in the environment to which patients may be exposed. This bacterium used to
        belong to the Clostridium genus, but analysis of its 16S ribosomal RNA in 2016 led to its
        being distinguished from it. Once the spore has been ingested, it can germinate in vegetative
        form (the active form of the bacterium), taking on the appearance of a Gram-positive bacillus
        that will colonize the digestive microbiota. This preliminary stage of digestive colonization
        by the bacteria is facilitated by certain factors, notably nasogastric probing, antacids,
        etc. Antibiotics, for their part, disrupt the bacteria of the digestive microbiota
        (dysbiosis), thus facilitating the implantation of C. difficile. Certain strains (known as
        toxigenic) will produce the main virulence factors: toxins A (TcdA) and B (TcdB) ± a third
        toxin (binary toxin or CDT), and thus cause the main clinical signs of digestive infection,
        particularly in patients with risk factors for C. difficile infection (progressive cancer,
        immunodepression, etc.).
  
        Clostridioides difficile infection (CDI) is characterized by variable clinical presentations,
        ranging from simple watery diarrhea without colitis, which often resolves spontaneously, to
        severe forms with complications such as pseudomembranous colitis, intestinal perforation or
        septic shock, which have a very poor prognosis.
  
        Management of this type of CDI relies mainly on the oral administration of anti-clostridium
        difficile antibiotics such as fidaxomicin (FDX) or vancomycin (VAN) for 10 days, as
        recommended by the European ESCMID, British and American IDSA guidelines. Oral metronidazole
        is recommended only in the absence of availability of the first two molecules (community
        use). Despite this treatment, one of the main characteristics of CDI is a high recurrence
        rate, which can reach 25% of cases. With FDX, recurrence rates appear to be lower, especially
        as its administration regimen is optimized. Nevertheless, its high cost is a barrier to its
        wider use.
  
        In view of the high cost to the community of treating recurrences, and the reduced quality of
        life of patients suffering from these recurrences, which are sometimes multiple and highly
        incapacitating, reducing the occurrence of recurrences is a major challenge. A better
        understanding of the factors leading to recurrence is therefore a prerequisite for optimizing
        CDI prevention and treatment strategies.
  
        The study of colonic mucosal immunity (aimed at quantifying IgA in stools) could also
        contribute to a better understanding of patient progress.
  
        All these issues surrounding CDI and its management justify the setting up of a prospective
        cohort for the longitudinal follow-up of infected patients, enabling us to study the
        digestive clearance of the bacteria according to various factors, notably the digestive
        microbiota and the mucosal immune response.
  observational model: Cohort
  time perspective: Prospective
  measure: Duration of delay between diagnosis of CDI and early or late elimination of C. difficile
  time frame: Month 2
  description: This outcome corresponds to the kinetics of C. difficile elimination, and the time taken for the various microbiological tests (EIA, immunochromatography (ICT), culturomic and specific qPCR tests) detecting C. difficile in stools to become negative, from the day of diagnosis (i.e. before treatment was started), during the 10-day treatment period and after the end of treatment.
  measure: Confronting digestive microbiota dysbiosis with C. difficile elimination kinetics
  time frame: Month 2
  description: This outcome corresponds to the comparison in terms of number and type of digestive microbiota as a function of C. difficile elimination kinetics before treatment (at the time of diagnosis), at the end of 10 days of CDI treatment and after the end of treatment.
  measure: Impact of antibiotics prescribed for the treatment of CDI after 10 days of treatment
  time frame: Day 10
  description: This outcome corresponds to the comparison in terms of number and type of diversity of digestive microbiota according to the type of anti-C. difficile antibiotic prescribed at the end of treatment, compared with the number and type of digestive observed at the time of diagnosis, i.e. before the start of treatment.
  measure: Determination of the form in which C. difficile persists in the digestive microbiota during treatment and after the end of treatment until it is eliminated.
  time frame: Month 2
  description: This outcome corresponds to the type of the bacterial form (vegetative or spore-forming) that persists during and after ICD treatment by qPCR, Propidium monoazide - qPCR (PMA-qPCR) (viable or dead bacteria) and culturomics until digestive clearance of the bacteria.
  measure: Evaluation of the colonic and salivary mucosal immune response of included patients, in relation to patient progress and C. difficile elimination kinetics.
  time frame: Month 2
  description: This outcome corresponds to the number of participants with a development of a C. difficile anti-toxin IgA response and correlation of colonic/salivary IgA levels after ICD with patient course (single, recurrent and severe forms) and C. difficile elimination kinetics.
  arm group label: Patients with Clostridioides infection
  description: The following procedures are specific to this test: 8 additional stool swabs (or Fecal Swab in the absence of stool output) to that of the initial diagnosis, plus four saliva swabs. Rectal swabs may cause anal irritation. The patient must also complete a stool collection form.
  additional stool samples (or Fecal Swab in the absence of stool output) to that of the
        initial diagnosis, as well as saliva samples
  study pop: 
  sampling method: Non-Probability Sample
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Assaf MIZRAHI, MD
  role: Principal Investigator
  affiliation: Fondation Hôpital Saint-Joseph
  last name: Assaf MIZRAHI, MD
  phone: 144127030
  phone ext: +33
  email: amizrahi@ghpsj.fr
  last name: Helene BEAUSSIER, PharmD, PhD
  phone: 144127883
  phone ext: +33
  email: crc@ghpsj.fr
  facility: 
  contact: 
  country: France
  url: https://www.gov.uk/government/consultations/clostridioides-difficile-infection-guidance-on-management-and-treatment
  description: Clostridioides difficile infection: guidance on management and treatment [Internet]. GOV.UK. 2022
  citation: Lawson PA, Citron DM, Tyrrell KL, Finegold SM. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Prevot 1938. Anaerobe. 2016 Aug;40:95-9. doi: 10.1016/j.anaerobe.2016.06.008. Epub 2016 Jun 28.
  PMID: 27370902
  citation: Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021 Sep 7;73(5):e1029-e1044. doi: 10.1093/cid/ciab549.
  PMID: 34164674
  citation: van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, Krutova M, Noren T, Allerberger F, Coia JE, Goorhuis A, van Rossen TM, Ooijevaar RE, Burns K, Scharvik Olesen BR, Tschudin-Sutter S, Wilcox MH, Vehreschild MJGT, Fitzpatrick F, Kuijper EJ; Guideline Committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect. 2021 Dec;27 Suppl 2:S1-S21. doi: 10.1016/j.cmi.2021.09.038. Epub 2021 Oct 20.
  PMID: 34678515
  citation: Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S; OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012 Apr;12(4):281-9. doi: 10.1016/S1473-3099(11)70374-7. Epub 2012 Feb 8.
  PMID: 22321770
  citation: Guery B, Menichetti F, Anttila VJ, Adomakoh N, Aguado JM, Bisnauthsing K, Georgopali A, Goldenberg SD, Karas A, Kazeem G, Longshaw C, Palacios-Fabrega JA, Cornely OA, Vehreschild MJGT; EXTEND Clinical Study Group. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. Lancet Infect Dis. 2018 Mar;18(3):296-307. doi: 10.1016/S1473-3099(17)30751-X. Epub 2017 Dec 19.
  PMID: 29273269
  citation: Guery B, Berger P, Gauzit R, Gourdon M, Barbut F; DAFNE study group; Dafne Study Group, Bemer P, Bessede E, Camou F, Cattoir V, Couzigou C, Descamps D, Dinh A, Laurans C, Lavigne JP, Lechiche C, Leflon-Guibout V, Le Monnier A, Levast M, Mootien JY, N'Guyen Y, Piroth L, Prazuck T, Rogeaux O, Roux AL, Vachee A, Vernet Garnier V, Wallet F. A prospective, observational study of fidaxomicin use for Clostridioides difficile infection in France. J Int Med Res. 2021 Jun;49(6):3000605211021278. doi: 10.1177/03000605211021278.
  PMID: 34162264
  citation: Watt M, Dinh A, Le Monnier A, Tilleul P. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France. J Med Econ. 2017 Jul;20(7):678-686. doi: 10.1080/13696998.2017.1302946. Epub 2017 Mar 16.
  PMID: 28299963
  citation: Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001 Jan 20;357(9251):189-93. doi: 10.1016/S0140-6736(00)03592-3.
  PMID: 11213096
  citation: Chilton CH, Crowther GS, Todhunter SL, Ashwin H, Longshaw CM, Karas A, Wilcox MH. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model. J Antimicrob Chemother. 2015 Sep;70(9):2598-607. doi: 10.1093/jac/dkv156. Epub 2015 Jun 14.
  PMID: 26078392
  citation: Le Monnier A, Candela T, Mizrahi A, Bille E, Bourgeois-Nicolaos N, Cattoir V, Farfour E, Grall I, Lecointe D, Limelette A, Marcade G, Poilane I, Poupy P, Kansau I, Zahar JR, Pilmis B; GMC Group. One-day prevalence of asymptomatic carriage of toxigenic and non-toxigenic Clostridioides difficile in 10 French hospitals. J Hosp Infect. 2022 Nov;129:65-74. doi: 10.1016/j.jhin.2022.05.011. Epub 2022 May 28.
  PMID: 35640734
  citation: Le Monnier A, Duburcq A, Zahar JR, Corvec S, Guillard T, Cattoir V, Woerther PL, Fihman V, Lalande V, Jacquier H, Mizrahi A, Farfour E, Morand P, Marcade G, Coulomb S, Torreton E, Fagnani F, Barbut F; GMC Study Group. Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals. J Hosp Infect. 2015 Oct;91(2):117-22. doi: 10.1016/j.jhin.2015.06.017. Epub 2015 Jul 22.
  PMID: 26253518
  citation: Meza-Torres J, Auria E, Dupuy B, Tremblay YDN. Wolf in Sheep's Clothing: Clostridioides difficile Biofilm as a Reservoir for Recurrent Infections. Microorganisms. 2021 Sep 10;9(9):1922. doi: 10.3390/microorganisms9091922.
  PMID: 34576818
  citation: Barbut F, Galperine T, Vanhems P, Le Monnier A, Durand-Gasselin B, Canis F, Jeanbat V, Duburcq A, Alami S, Bensoussan C, Fagnani F. Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting. Health Qual Life Outcomes. 2019 Jan 11;17(1):6. doi: 10.1186/s12955-019-1081-5.
  PMID: 30634997
  citation: Debast SB, Bauer MP, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014 Mar;20 Suppl 2:1-26. doi: 10.1111/1469-0691.12418.
  PMID: 24118601
  citation: Sethi AK, Al-Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect Control Hosp Epidemiol. 2010 Jan;31(1):21-7. doi: 10.1086/649016.
  PMID: 19929371
  citation: Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis. 1996 May;22(5):813-8. doi: 10.1093/clinids/22.5.813. Erratum In: Clin Infect Dis 1996 Aug;23(2):423.
  PMID: 8722937
  citation: Saha S, Yadav D, Pardi R, Patel R, Khanna S, Pardi D. Kinetics of polymerase chain reaction positivity in patients with Clostridioides difficile infection. Therap Adv Gastroenterol. 2021 Oct 8;14:17562848211050443. doi: 10.1177/17562848211050443. eCollection 2021.
  PMID: 34646361
  citation: Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000 Feb 10;342(6):390-7. doi: 10.1056/NEJM200002103420604.
  PMID: 10666429
  citation: Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB; MODIFY I and MODIFY II Investigators. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med. 2017 Jan 26;376(4):305-317. doi: 10.1056/NEJMoa1602615.
  PMID: 28121498
  citation: Ahluwalia B, Magnusson MK, Ohman L. Mucosal immune system of the gastrointestinal tract: maintaining balance between the good and the bad. Scand J Gastroenterol. 2017 Nov;52(11):1185-1193. doi: 10.1080/00365521.2017.1349173. Epub 2017 Jul 12.
  PMID: 28697651
  citation: Nibbering B, Gerding DN, Kuijper EJ, Zwittink RD, Smits WK. Host Immune Responses to Clostridioides difficile: Toxins and Beyond. Front Microbiol. 2021 Dec 21;12:804949. doi: 10.3389/fmicb.2021.804949. eCollection 2021.
  PMID: 34992590
  citation: Bridgman SL, Konya T, Azad MB, Guttman DS, Sears MR, Becker AB, Turvey SE, Mandhane PJ, Subbarao P; CHILD Study Investigators; Scott JA, Field CJ, Kozyrskyj AL. High fecal IgA is associated with reduced Clostridium difficile colonization in infants. Microbes Infect. 2016 Sep;18(9):543-9. doi: 10.1016/j.micinf.2016.05.001. Epub 2016 May 24.
  PMID: 27235197
  responsible party type: Sponsor
  mesh term: Infections
  mesh term: Communicable Diseases
  mesh term: Clostridium Infections